Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
CDKN1A, CDKN1, CIP1, CDK-interacting protein 1, DNA synthesis inhibitor, p21CIP1, MDA6, PIC1, SDI1, WAF1, CAP20, CDK-interaction protein 1, MDA-6, p21
(tested or 100% immunogen sequence identity)
Protein A/G purified
Synthetic peptide derived from human p21
Specifically binds to its immunogen, and does not show any cross reactivity with unrelated antigens. The specificity for binding to recombinant protein, cellular protein and native antigen is not defined. Cross reactivity with mouse and rat p21 has not been tested.
The applications listed have been tested for the unconjugated form of this product. Other forms have not been tested.
No preservative stabilizers
Short term 4°C, long term aliquot and store at -20°C, avoid freeze-thaw cycles.
CDKN1A / WAF1 / p21 is a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli.